Stephen Munk

Miller, S.; Moos, W.; Munk, B.; Munk, S. “Managing the Drug Discovery Process: How to Make it more Efficient and Cost-Effective. Woodhead Publishing, an Imprint of Elsevier, 2016.

Munk, S.A. “The Role of the Chemical Development, Quality, and Regulatory Affairs Team in Turning a Potent Agent into a Registered Product” in COMPREHENSIVE MEDICINAL CHEMISTRY II, Volume 2: Research and Development; Moos, W.H. Volume Ed.; Taylor, J.B. and Triggle, D.J. Eds. Elsevier, Oxford; 2007.

Ammoscato, V.; Wickenheiser, R.; Henderson, J.; Munk, S. “State-of-the-Art Process for the Safe Synthesis of Anticancer Drugs” Drug Dev. Res. 2010 71, 1.

Thompson, C.D.; Macdonald T.L., Garst, M.E.; Wiese A.; Munk, S.A. “Mechanisms of Adrenergic Agonist Induced Allergy; Bioactivation and Antigen Formation” Exp. Eye Res., 1997 64, 767.

Thompson, C.D.; Vachaspati, P.R.; Kolis, S.P.; Gulden, P.H.; Garst, M.E.; Wiese, A.; Munk, S.A.; Harmon, W.D.; Macdonald, T.L. “Mechanisms of Adrenergic Agonist Induced Allergy: Bioactivation and Antigen Formation” Chem. Res. Toxicol. 1997 10, 1032.

Munk, S.A.; Harcourt, D. Arasasingham, P.N.; Burke, J.A.; Kharlamb, A.; Manlapaz, C.; Padillo, E.U.; Roberts, D.; Runde, E.; Williams, L.; Wheeler, L.; Garst, M.E. “Synthesis and Evaluation of N-Aryl Aminoimidazoles as a2-Adrenoceptor Agonists” J. Med. Chem., 1997 40, 18.

Acheampong, A.A.; Chien, D.-S.; Lam, S.; Vekich, S.; Breau, A.; Usansky, J.; Harcourt, D.; Munk, S.A.; Nguyen, H.; Garst, M.; Tang-Liu, D. “Brimonidine Metabolism with Rat, Rabbit, Dog, Monkey, and Human Liver Fractions and Aldehyde Oxidase, and Structural Characterization of Metabolites” Xenobiotica 1996 26, 1035.

Munk, S.A.; Harcourt, D.; Ambrus, G.; Denys, L.; Gluchowski, C.; Burke, J.A.; Kharlamb, A.; Manlapaz, C.; Padillo, E.; Runde, E.; Wheeler, L.; Garst, M.E. “Synthesis and Evaluation of 2-(5-methyl-benz-1-ox-4-azin-6-yl)imino imidazoline: A Potent, Peripherally Acting a2-Adrenoceptor Agonist” J. Med. Chem. 1996 39, 3533.

Munk, S.A.; Lai, R.; Burke, J.; Arasasingham, P.; Kharlamb, A.; Manlapaz, C.; Wijono, M.; Wheeler, L.; Garst, M. “Synthesis and Pharmacologic Evaluation of AGN 192403: A potent Imidazoline1 Receptor Specific Agent” J. Med. Chem. 1996 39, 1193.

Munk, S.A.; Harcourt, D.; Arasasingham, P. Gluchowski, C.; Wong, H.; Burke, J.; Kharlamb, A.; Manlapaz, C.; Padillo, E.; Williams, L.; Wheeler, L.; Garst, M. “Analogs of UK 14,304: Structural Features Responsible for a2-Adrenoceptor Activity” BioMedChem. Lett. 1995 5, 1745.

Sullivan, R.W.; Coghlan, V.M.; Munk, S.A.; Reed, M.W.; Moore, H.W. “DNA Cleavage by 4-Alkynyl-3-methoxy-4-hydroxycyclobutenes” J. Org. Chem. 1994 59, 2276.

Munk, S.A.; Gluchowski, C.; Dolby, L.; Wong, H.; Burke, J.; Kharlamb, A.; Manlapaz, C.; Padillo, E.; Rodgers, D.; Ohta, B.; Wheeler, L.; Garst, M. “Analogs of UK 14,304 as a2-Adrenoceptor Agonists.  Twist and Agent Polarity as Design Elements” BioMedChem. Lett. 1994 4, 459.

Boger, D.L.; Munk, S.A.; “DNA Alkylation Properties of Enhanced Functional Analog of CC-1065 Incorporating the 1,2,9,9a-Tetrahydrocycloprop[1,2-c] benz[1,2-e]indole-4-one (CBI) Alkylation Subunit” J. Amer. Chem. Soc. 1992 114, 5487.

Boger, D.L.; Ishizaki, T.; Sakya, S.M.; Munk, S.A.; Kitos, P.A.; Jin, Q.; Besterman, J. “Synthesis and Preliminary Evaluation of (+)-CBI-Indole2: an Enhanced Functional Analog of (+)-CC-1065” BioMedChem. Lett. 1991 1, 115.

Boger, D.L.; Munk, S.A.; Zarrinmayah, H. “(+)-CC-1065 DNA Alkylation: Key Studies Demonstrating a Noncovalent Binding Selectivity Contribution to the Alkylation Selectivity” J. Amer. Chem. Soc. 1991 113, 3980.

Boger, D.L.; Munk, S.A.; Zarrinmayah, H.; Ishizaki, T.; Haught, J.; Bina, M. “An Alternative and Convenient Strategy for Generation of Substantial Quantities of Singly 5'-32P-End-Labeled Double-Stranded DNA for Binding Studies: Development of a Protocol for Examination of Functional Features of (+)-CC-1065 and Duocarmycins that Contribute to Their Sequence-Selective DNA Alkylation Properties” Tetrahedron 1991 47, 2661.

Boger, D.L.; Munk, S.A.; Ishizaki, T. “The (+)-CC-1065 DNA Alkylation: Observation of an Unexpected Relationship Between Cyclopropane Electrophile Reactivity and Intensity of DNA Alkylation” J. Amer. Chem. Soc. 1991 113, 2779.

Boger, D.L.; Zarrinmayah, H.; Munk, S.A.; Kitos, P.A.; Suntornwat, O. “Demonstration of a Pronounced Effect of Noncovalent Binding Selectivity on the (+)-CC-1065 DNA Alkylation and Identification of the Pharmacophore of the Alkylation Subunit” Proc. Natl. Acad. Sci. U.S.A. 1991 88, 1431.

Boger, D.L.; Ishizaki, T.; Zarrinmayah, H.; Munk, S.A.; Kitos, P.A.; Suntornwat, O. “Duocarmycin-Pyrindamycin DNA Alkylation Properties and Identification, Synthesis, and Evaluation of Agents Incorporating the Pharmacophore of the Duocarmycin/Pyrindamycin Alkylation Subunit.  Identification of the CC-1065-Duocarmycin Common Pharmacophore” J. Amer. Chem. Soc. 1990 112, 8961.

Boger, D.L.; Coleman, R.S.; Invergo, B.J.; Ishizaki, T.; Munk, S.A.; Sakya, S.M.; Zarrinmayah, H.; Kitos, P.A.; Thompson, S.C. “Synthesis and Evaluation of Aborted and Extended CC-1065 Functional Analogs: (+)- and (-)-CPI-PDEI1, (+)/-)-, (+)-, and (-)-CPI-CDPI3. Preparation of Key Partial Structures and Definition of an Additional Functional Role of the CC-1065 Central and Right-Hand Subunits” J. Amer. Chem. Soc. 1990 112, 4623.

Boger, D.L.; Ishizaki, T.; Wysocki, R.J.; Munk, S.A.; Kitos, P.A.; Suntornwat, O. “Total Synthesis and Evaluation of (+/-)-N-(tert-Butyloxycarbonyl)-CBI, (+/-)-CBI-CDPI1, and (+/-)-CBI-CDPI2: CC-1065 Functional Agents Incorporating the Equivalent 1,2,9,9a-Tetrahydrocyclopro[1,2-c]benz[1,2-e]indol-4-one (CBI) Left-Hand Subunit” J. Amer. Chem. Soc. 1989 111, 6461.